Self-administered injectable contraceptives, which are progestin-only shots taken at home every three months, have been ...

Investing.com -- The U.S. Food and Drug Administration (FDA) approved Zycubo (copper histidinate) injection on Monday as the ...

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserve ...

Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of ...

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...

The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American ...

ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ...

Inhaled insulin Afrezza has launched in India, offering a needle-free option for diabetes management. Designed to overcome ...